One example of a process where lipid rafts are believed to play a crucial role is the formation of an immunological synapse between a T-cell and an Antigen Presenting Cell
(APC) - a process which requires major structural rearrangements within the cell and the recruitment and recycling of numerous signalling molecules.
Immutep's efti is a first-in-class antigen presenting cell
("APC") activator which stimulates cancer-fighting T cells, while KEYTRUDA is an anti-PD-1 therapy helps the body's immune system to detect and fight tumor cells.
The effect of antigen size on the immunogenicity of antigen presenting cell
targeted DNA vaccine.
The recognition of bacterial and viral products by Toll-like receptors on cells of the innate immune system also results in NF-KappaB induction, leading to the production of proinflammatory cytokines and the activation of Antigen Presenting Cell
for T-Cell costimulation in the adaptive immune response.
Abatacept (Orencia[R], Bristol-Myers Squibb) is a selective T-cell costimulation modulator that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80/86 ligand on the antigen presenting cell
Moreover, Macrophage is an Antigen Presenting Cell
which activates adaptive immune response (Henry&Albert,2008),(Paul,2008),and Mast Cell belongs to the family of Basophil, Neutrophil and Eosinophil and present near the boundaries between the body and the outside world.
and the international Ludwig Institute for Cancer Research (LICR) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell
(APC) Targeting Technology.
Impaired antigen-induced CD[8.sup.+] T cell clonal expansion in aging is due to defects in antigen presenting cell
The expanded peptide-specific regulatory cells shut down the autoimmune attack by preventing aggressive autoimmune cells from being stimulated by either the peptide contained in the vaccine or by any other type 1 diabetes autoantigen presented simultaneously on the same antigen presenting cell
IMP321, a first-in-class Antigen Presenting Cell
(APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy.
Th are activated when they encounter protein presented to them by an antigen presenting cell
IMP321, which is a soluble form of LAG-3, is an antigen presenting cell
activator that induces T cell immunostimulation for cancer chemoimmunotherapy.